Frevecitinib
CAS 1299417-07-4
MF C22H21N7O2 MW 415.4 g/mol
3-[(3S)-3-(1-methyl-2-oxo-5-pyrazolo[1,5-a]pyridin-3-ylimidazo[4,5-b]pyridin-3-yl)piperidin-1-yl]-3-oxopropanenitrile
3-{(3S)-3-[1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridin-3-
yl)-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl]piperidin1-yl}-3-oxopropanenitrile
Janus kinase inhibitor, anti-inflammatory, 5N5L287M8T, KN 002, KN-002
Single and Multiple Ascending Dose Study of KN-002
CTID: NCT05006521
Phase: Phase 1
Status: Completed
Date: 2024-08-07
SYN
https://patentscope.wipo.int/search/en/detail.jsf?docId=US210080653&_cid=P11-MH2U9I-58146-1
It has now been found that a drug substance disclosed in WO2011/051452, namely the compound (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridine-3-yl)-1H-imidazo[4,5-b]pyridine-3(2H)-yl)piperidin-1-yl)-3-oxopropanenitrile having the structure shown below and known herein as compound (I) can be prepared in different polymorphic forms. Surprisingly one form exists as a polymorph with particularly advantageous stability properties. Compound (I) as prepared following the process in WO2011/051452 is known as Form I herein.
SYN
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2011157397&_cid=P11-MH2TVG-48083-1
SYN
https://patentscope.wipo.int/search/en/detail.jsf?docId=US76222175&_cid=P11-MH2U0A-51623-1
PAT
- N-containing heteroaryl derivatives as jak3 kinase inhibitorsPublication Number: KR-101675614-B1Priority Date: 2009-10-29Grant Date: 2016-11-11
- N-containing heteroaryl derivatives as jak3 kinase inhibitorsPublication Number: US-2012245140-A1Priority Date: 2009-10-29
- N-containing heteroaryl derivatives as jak3 kinase inhibitorsPublication Number: US-2013131038-A9Priority Date: 2009-10-29
- N-containing heteroaryl derivatives as JAK3 kinase inhibitorsPublication Number: US-8501735-B2Priority Date: 2009-10-29Grant Date: 2013-08-06
- N-containing heteroaryl derivatives as JAK3 kinase inhibitorsPublication Number: US-8946257-B2Priority Date: 2009-10-29Grant Date: 2015-02-03
- Heteroaryl imidazolone derivatives as jak inhibitorsPublication Number: EP-2582703-A1Priority Date: 2010-06-15
- Heteroaryl Imidazolone Derivatives as Jap InhibitorsPublication Number: KR-20130113331-APriority Date: 2010-06-15
- Heteroaryl imidazolone derivatives as jak inhibitorsPublication Number: US-2013089512-A1Priority Date: 2010-06-15
- Heteroaryl imidazolone derivatives as jak inhibitorsPublication Number: WO-2011157397-A1Priority Date: 2010-06-15
- N-containing heteroaryl derivatives as jak3 kinase inhibitorsPublication Number: EP-2493895-B1Priority Date: 2009-10-29Grant Date: 2017-04-26
- Novel polymorphsPublication Number: US-2018016284-A1Priority Date: 2015-02-05
- Novel polymorphsPublication Number: US-2019031687-A1Priority Date: 2015-02-05
- Novel polymorphsPublication Number: WO-2016124464-A1Priority Date: 2015-02-05
- Heteroaryl imidazolone derivatives as jak inhibitorsPublication Number: CA-2802588-A1Priority Date: 2010-06-15
- Heteroaryl imidazolone derivatives as JAK inhibitorsPublication Number: CN-102933583-APriority Date: 2010-06-15
- Novel polymorphsPublication Number: EP-3053927-A1Priority Date: 2015-02-05
- Novel polymorphsPublication Number: EP-3253769-B1Priority Date: 2015-02-05Grant Date: 2019-03-13
- New polymorphPublication Number: JP-2018502929-APriority Date: 2015-02-05
- New polymorphPublication Number: JP-6685326-B2Priority Date: 2015-02-05Grant Date: 2020-04-22
- PolymorphsPublication Number: US-10087196-B2Priority Date: 2015-02-05Grant Date: 2018-10-02
- Crystalline form of a JAK3 kinase inhibitorPublication Number: US-10155757-B2Priority Date: 2015-03-10Grant Date: 2018-12-18
- Crystalline form of a jak3 kinase inhibitorPublication Number: US-2018044336-A1Priority Date: 2015-03-10
- Crystalline form of a jak3 kinase inhibitorPublication Number: WO-2016142201-A1Priority Date: 2015-03-10
- Polymorphic forms of (s)-3-(3(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridine-3(2h)-yl)piperidin-1-yl)-3-oxopropanenitrilePublication Number: CA-2972977-CPriority Date: 2015-02-05Grant Date: 2019-04-09
- polymorphPublication Number: CN-107207533-BPriority Date: 2015-02-05Grant Date: 2019-04-16
- Formulation of a pan-jak inhibitorPublication Number: TW-202440105-APriority Date: 2022-12-02
- Formulation of a pan-jak inhibitorPublication Number: US-2024261224-A1Priority Date: 2022-12-02
- Formulation of a pan-jak inhibitorPublication Number: WO-2024119058-A2Priority Date: 2022-12-02
- Formulation of a pan-jak inhibitorPublication Number: WO-2024119058-A3Priority Date: 2022-12-02
- Crystalline form of a jak3 kinase inhibitorPublication Number: EP-3268364-A1Priority Date: 2015-03-10
AS ON JUNE2025 4.45 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
……
///////////Frevecitinib, Janus kinase inhibitor, anti-inflammatory, 5N5L287M8T, KN 002, KN-002